The development of diabetes mellitus with the chronic use of atypical antipsychotics in patients from CAPS II, in the city of Maringá-PR
DOI:
https://doi.org/10.33448/rsd-v12i10.43283Keywords:
Schizophrenia; Mental disorders; Diabetes mellitus; Antipsychotic agents.Abstract
Schizophrenia is a chronic, multifactorial condition prevalent in 1% of the global population. Treatment is carried out with conventional or atypical antipsychotics. The evolution in the treatment of schizophrenia has occurred with atypical antipsychotics, as they offer fewer side effects and allow for simultaneous action on both the positive and negative symptoms of the disease. These drugs are used for the control of schizophrenia as well as other psychopathologies, for example, Bipolar Affective Disorder (ICD-10 F31). The labels of antipsychotic medications warn against the use of the medication in diabetic patients or those at risk of developing diabetes, recommending glycemic monitoring for such patients. As a result of this effect, the present study aims to gather information about the development of diabetes due to the use of atypical antipsychotics for the treatment of schizophrenia, schizotypal disorders, delusional disorders, and other disorders resembling schizophrenia. This is a descriptive research with quantitative analysis, focusing on bibliographic data and field research, in which data were collected through medical records of patients in the coverage area of the Psychosocial Care Center (CAPS II) in the city of Maringá, PR. The results found through this study include the side effects of the medications, their relationship with age, gender, dosage, and duration of use. Furthermore, the multifactorial influence on the development of other comorbidities can be observed. This can contribute to providing proper guidance, emphasizing the harm that the improper administration of these medications can cause.
References
Barbosa, A. M. & Portela R. G. (2021). Eficácia e segurança de aripiprazol comparado aos antipsicóticos disponíveis no SUS para tratamento de esquizofrenia em adultos: revisão rápida de evidências. Revista Científica da Escola Estadual de Saúde Pública de Goiás - “Candido Santiago”, 7(1), 1-16. https://doi.org/10.22491/2447-3405.2021.V7.7000048
Bertoni, R. A. & Leal, F. M. (2023). Revisão do tratamento da esquizofrenia: monoterapia vs associação de antipsicóticos. Debates em Psiquiatria. 13, 1-20. https://doi.org/10.25118/2763-9037.2023.v13.414
Brasil. Ministério da Saúde (2008). F20-F29 Esquizofrenia, transtornos esquizotípicos e transtornos delirantes. http://www2.datasus.gov.br/cid10/V2008/WebHelp/f20_f29.htm
Brunton, L. L., Hilal-Dandan, R. & Knollmann, B. C. (2019). As Bases Farmacológicas da Terapêutica de Goodman e Gilman. Artmed.
Buda, L. F. S. (2023). Tratamento da Esquizofrenia: monoterapia versus associação de antipsicóticos – revisão de literatura. Brazilian Journal of Health Review, 6(3), 9115–9120. https://doi.org/10.34119/bjhrv6n3-060
Dalgalarrondo, P. (2008). Psicopatologia e semiologia dos transtornos mentais. Artmed.
Doménech-Matamoros P. (2020). Influence of the use of atypical antipsychotics in metabolic syndrome. Revista espanola de sanidad penitenciaria, 22(2), 80–86. https://doi.org/10.18176/resp.00014
Fulone, I., Silva, M. T., & Lopes, L. C. (2023). Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017. Epidemiologia E Serviços De Saúde, 32(1), e2022556. https://doi.org/10.1590/S2237-96222023000300015
Grilo, R. R. da C. (2020). Efeitos adversos metabólicos dos antipsicóticos atípicos: uma revisão da literatura (Trabalho de Conclusão de Curso, Universidade de Brasília, Brasília, DF). Recuperado de http://dx.doi.org/10.26512/2020.TCC.28598
Junior, C. G. K. & Rosar, P. A. (2020). Perfil demográfico de distribuição de antipsicóticos de segunda geração para pacientes com Transtorno Afetivo Bipolar, Transtorno Esquizoafetivo e Esquizofrenia em Santa Catarina (Trabalho de Conclusão de Curso, Universidade do Sul de Santa Catarina, Palhoça, SC). Recuperado de https://repositorio.animaeducacao.com.br/handle/ANIMA/9254
Mari, J. J., & Leitão, R. J. (2000). A epidemiologia da esquizofrenia. Brazilian Journal of Psychiatry, 22, 15–17. https://doi.org/10.1590/S1516-44462000000500006
Mendonça, A. M., Moura, J. A., Araújo, P. B. de O. & Almeida, S. D. (2022). Environmental and genetic factors associated with the development of Type 2 Diabetes mellitus: systematic review. Research, Society and Development, 11(16), e257111638325. https://doi.org/10.33448/rsd-v11i16.38325
Merchán-Hamann, E. & Tauil, P. L. (2021). Proposta de classificação dos diferentes tipos de estudos epidemiológicos descritivos. Epidemiologia E Serviços De Saúde, 30(1), e2018126. https://doi.org/10.1590/s1679-49742021000100026
Narváez, A. A. V., Chamorro, G. A., & López, L. M. R. (2020). Diabetes mellitus asociada al uso crónico de antipsicóticos atípicos. Revista Médica de Risaralda, 26(2), 148-153. https://doi.org/10.22517/25395203.24439
Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J. & Henderson, G. (2012). Rang & Dale Farmacologia. Elsevier.
Sadok, B. J., Sadok, V. A., & Ruiz, P. (2017). Compêndio de psiquiatria: ciência do comportamento e psiquiatria clínica. Artmed.
Sena, E. P. de., Sampaio, A. S., Quarantini, L. de C., & Oliveira, I. R. de. (2003). Diabetes mellitus e antipsicóticos atípicos. Brazilian Journal of Psychiatry, 25(4), 253–257. https://doi.org/10.1590/S1516-44462003000400014
Silva, R. C. B. da. (2006). Esquizofrenia: uma revisão. Psicologia USP, 17(4), 263–285. https://doi.org/10.1590/S0103-65642006000400014
Teixeira, P. J. R. & Rocha, F. L. (2006). Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor. Revista De Psiquiatria Do Rio Grande Do Sul, 28(2), 186–196. https://doi.org/10.1590/S0101-81082006000200011
Wannmacher, L. (2004). Antipsicóticos atípicos: mais eficazes, mais seguros? Uso racional de medicamentos. 1(12). https://bvsms.saude.gov.br/bvs/publicacoes/HSE_URM_APS_1104.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mariana Teixeira Leal Batista Olivieri ; Ana Elisa Ress Socio Vieira; Emilene Dias Fiuza Ferreira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
